Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKinsey
Chinese Patent Office
Baxter
Express Scripts
Farmers Insurance
Chubb
Fuji
Healthtrust

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,579,865

« Back to Dashboard

Which drugs does patent 6,579,865 protect, and when does it expire?

Patent 6,579,865 protects FORTESTA and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.
Summary for Patent: 6,579,865
Title: Penetration enhancing and irritation reducing systems
Abstract:This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.
Inventor(s): Mak; Vivien H. W. (Menlo Park, CA), Grayson; Stephen (San Rafael, CA)
Assignee: Cellegy Pharmaceuticals, Inc. (So. San Francisco, CA)
Application Number:09/963,287
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,579,865
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 6,579,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharms FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,579,865

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,319,913 Penetration enhancing and irritation reducing systems ➤ Sign Up
7,157,097 Penetration enhancing and irritation reducing systems ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,579,865

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 9924041 ➤ Sign Up
New Zealand 504423 ➤ Sign Up
Portugal 1510213 ➤ Sign Up
Norway 20002422 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
Argus Health
Covington
Chubb
Queensland Health
Healthtrust
McKesson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.